Mindfulness Meditation Reduces Suffering In Chronic Migraineurs: Study

Migraine Meditation

Studies Show Meditation Helps Migraineurs (1)

A study conducted by researchers at Wake Forest Baptist Medical Center, Winston-Salem, NC, and Harvard Medical School in Boston, MA, examined 19 adults suffering from chronic migraines in order to find the effects of mindfulness meditation on those experiencing chronic headaches and to test the safety and feasibility of such a practice.

The findings of this study were published online in journal Headache.  Such a test was conducted mainly keeping in mind the hypothesis that stress-trigger in migraines could be addressed mindfulness meditation. As per lead author of the study, Rebecca Erwin Wells, assistant professor of neurology at Wake Forest Baptist, “Stress is a well-known trigger for headaches and research supports the general benefits of mind/body interventions for migraines, but there hasn’t been much research to evaluate specific standardized meditation interventions”. (2)

The study however demonstrated that mindfulness meditation did indeed help alleviate migraine pains and that they were a safe way to reduce the intensity and frequency of the migraines.

Mindfulness-based Stress Reduction or MBSR used yoga, mindfulness meditation and body awareness in a standardized 8-week program on the migraining volunteers. The migraineurs were divided into any of the 2 groups. They were then evaluated on disability, self-efficacy and mindfulness. After this was done, one group received conventional or mainstream migraine management care while the other group took part in the 8-week MBSR program. The MBSR program required the candidates to practice their mindfulness techniques for 45 minutes every day for at least 5 days a week. They were exposed to 1 instruction class every week as well. During this 8-week program all the participants noted how frequent their migraine episodes were, how long they lasted, how intense they were.

The researchers found that the patients who completed the MBSR program tended to have 1.4 fewer headaches per month that were less severe. Not only this, the episodes lasted less longer, were less disabling, the migraineurs felt a better sense of control over the events. Besides this, the program with its techniques proved safe as no adverse side effects were observed during the trial.

However, larger sample sizes and population with varied ethnicity, age groups, gender and socio-economic strata need to be studied for MBSR to be integrated into the mainstream and conventional treatment package for migraineurs.

According to Prof. Wells, “For the approximate 36 million Americans who suffer from migraines, there is a big need for non-pharmaceutical treatment strategies, and doctors and patients should know that MBSR is a safe intervention that could potentially decrease the impact of migraines.” (3)

SOURCES

  1. Image Credit: Woman Doing Yoga On Rock Stock Photo by Adamr; Free Digital Photos; Web September 2014; http://www.freedigitalphotos.net/images/Healthy_Living_g284-Woman_Doing_Yoga_On_Rock_p100414.html
  2. Migraine sufferers may find meditation helps; Medical News Today: Web September 2014; http://www.medicalnewstoday.com/articles/282441.php
  3. Meditation May Mitigate Migraine Misery;Wake Forest Baptist Medical Center – News & Media Resources; Web September 2014; http://www.wakehealth.edu/News-Releases/2014/Meditation_May_Mitigate_Migraine_Misery.htm

Copyrights apply to this blog. Please refer copyright permissions.

Advertisements

OptiNose – New Migraine Treatment: Data Presented At IHC 2013

TE_optinoseOptiNose’s Breath Powered Nasal Delivery Device (1)

Drug delivery technology corporation OptiNose Inc. has presented results of a pivotal phase III TARGET study at the International Headache Congress at Boston comparing both the efficacy and the safety of it’s newly developed technology – the OptiNose Breath Powered nasal delivery device with other drug delivery systems and placebos. The abstracts are to be published in Cephalalgia, the Journal of the International Headache Society

The breath-powered device containing low dose sumatriptan was used to deliver the drug in patients experiencing moderate to severe migraine pain, and then compared to placebo administered via the same route later.

According to Ramy A. Mahmoud, M.D., M.P.H., Chief Operating Officer of OptiNose, “Various data we are presenting today will highlight how this novel delivery technology improves the delivery of medicine to hard-to-reach regions deep in the nasal cavity, how it can produce fast and efficient absorption of medicine into the blood, and how effective treatment with this technology can be. There are nearly 30 million migraine sufferers in the United States and many will be able to benefit from a new low-dose treatment that can rapidly provide effective pain relief with few adverse events.” (2)

Sections discussed in the International Headache Congress 2013 included:

  • Efficacy and Safety of a Novel Breath Powered Powder Sumatriptan Intranasal Treatment for Acute Migraine;
  • Data from a randomized, single-dose, four-way cross-over study assessing the absorption into the blood of sumatriptan intranasal powder administered using the  Breath Powered OptiNose drug delivery device compared to Imitrex® subcutaneous injection, Imitrex nasal spray and Imitrex oral tablets in healthy adult volunteers.
  • A review of evidence for human in vivo drug deposition patterns in different regions of the nose with devices intended to provide reliable and efficient drug delivery to upper/posterior nerve structures deep in the nasal cavity.

To know more about the TARGET study, please visit the OptiNose website link given below. (3)

SOURCES:

  1. Image Credit: Nansen Neuroscience Netwrok; Optinose: Novel Nasal Drug Delivery device; Web June 2013; http://www.nansenneuro.net/news/member-news/285-novel-nasal-drug-delivery-device.html
  2. OptiNose AS to Present Data Highlighting New Migraine Treatment at International Headache Congress; BioSpace.com; Web June 2013; http://www.biospace.com/news_story.aspx?StoryID=301426&full=1
  3. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating The Efficacy And Safety Of A Single 20 Mg Dose Of Sumatriptan Powder Delivered Intranasally With The Bi-Directional Device In Adults With Acute Migraine With Or Without Aura; TARGET Phase III Study; Optinose.com; Web June 2013; http://www.optinose.com/clinical-trials/target-clinical-trial-for-migraine

TO VIEW THE MULTIMEDIA CONTENT ASSOCIATED WITH THIS RELEASE, PLEASE CLICK: http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions/.

 Copyrights apply on this blog. Please read copyright permissions.